You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The data are from two clinical trials and an expanded access program evaluating derazantinib in certain patients with intrahepatic cholangiocarcinoma.
The Phase I/II trial will assess the safety, recommended dose, initial efficacy, and pharmacokinetics of the autologous T-cell therapy ET140203 Artemis.
The company said data from the Phase II portion of the CodeBreak-100 study in KRAS-mutated lung cancer patients was positive and may be registrational.
The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.
The Phase I/II trial will assess the safety and efficacy of the CAR T cell therapy MB-102 for patients with three types of hematologic malignancies.
The firms will collaborate on identifying patients with NRG1 fusion-positive tumors and turn local cancer centers into study sites for the CRESTONE trial.
The Swiss company will assess the agent both alone and combined with Tecentriq as a treatment for FGFR-positive gastric cancer.
The randomized trial will assess the glutaminase inhibitor plus standard-of-care versus standard-of-care alone in patients with KEAP1- or NRF2-mutated tumors.
The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.
Although the benefit seen in the CAVE study needs Phase III confirmation, the analysis showed that plasma ctDNA testing may help identify best responders.